{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:22:59Z","timestamp":1791397379237,"version":"4.3.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,4,4]],"date-time":"2007-04-04T00:00:00Z","timestamp":1175644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,4,4]],"date-time":"2007-04-04T00:00:00Z","timestamp":1175644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1007\/s00280-007-0469-9","type":"journal-article","created":{"date-parts":[[2007,4,3]],"date-time":"2007-04-03T09:14:35Z","timestamp":1175591675000},"page":"129-134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study"],"prefix":"10.1007","volume":"60","author":[{"given":"Jong Gwang","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kyun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Soo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Young","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok Hwan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeoung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Seop","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goon Jae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Don","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hak","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk Joong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,4,4]]},"reference":[{"key":"469_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1056\/NEJM199211053271903","volume":"327","author":"LI Gordon","year":"1992","unstructured":"Gordon LI, Harrington D, Anderson J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, M Barcos, Gottlieb A (1992) Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin\u2019s lymphoma. N Engl J Med 327:1342\u20131349","journal-title":"N Engl J Med"},{"key":"469_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med 328:1002\u20131006","journal-title":"N Engl J Med"},{"key":"469_CR3","first-page":"809","volume":"30","author":"CH Lee","year":"1998","unstructured":"Lee CH, Im YH, Ryoo BY, Nam SM, Kim MS, Lee YS, Oh KK, Shim YS, Yoo SY, Lee JO, Kang YK (1998) Primary CHOP chemotherapy followed by involved field radiation therapy in clinical stage I or II aggressive non-Hodgkin\u2019s lymphomas. Cancer Res Treat 30:809\u2013817","journal-title":"Cancer Res Treat"},{"key":"469_CR4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA (1994) A revised European\u2013American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361\u20131392","journal-title":"Blood"},{"key":"469_CR5","doi-asserted-by":"crossref","unstructured":"Melnyk A, Rodrguez A, Pugh WC, Cabannillas F. Evaluation of the revised European\u2013American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin\u2019s lymphoma. Blood 89:4514\u20134520","DOI":"10.1182\/blood.V89.12.4514"},{"key":"469_CR6","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825\u20132833","journal-title":"J Clin Oncol"},{"key":"469_CR7","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 23:4117\u20134126","journal-title":"J Clin Oncol"},{"key":"469_CR8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/jcp.47.4.313","volume":"47","author":"JR Salisbury","year":"1994","unstructured":"Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin\u2019s lymphomas. J Clin Pathol 47:313\u2013317","journal-title":"J Clin Pathol"},{"key":"469_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","volume":"22","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky V (1998) Levels of expression of CD 52 in normal and leukemic B and T cells: correlations with in vivo therapeutic responses to Campath-1H. Leuk Res 22:185\u2013191","journal-title":"Leuk Res"},{"key":"469_CR10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","volume":"100","author":"J Lundin","year":"2002","unstructured":"Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, Mollgard L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath) as first line treatment for patients with B-cell chronic lymphocytic leukemia. Blood 100:768\u2013773","journal-title":"Blood"},{"key":"469_CR11","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","volume":"98","author":"CE Dearden","year":"2001","unstructured":"Dearden CE, Matutes E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D (2001) High remission rate in T-cell prolymphocytic leukemia with Campath-1H. Blood 98:1721\u20131726","journal-title":"Blood"},{"key":"469_CR12","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","volume":"101","author":"J Lundin","year":"2003","unstructured":"Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, Rosenblad E, Tjonnfjord G, Wiklund T, Osterborg A (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome. Blood 101:4267\u20134272","journal-title":"Blood"},{"key":"469_CR13","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","volume":"103","author":"G Enblad","year":"2004","unstructured":"Enblad G, Hagberg H, Erlanson M, Lunding J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103:2920\u20132924","journal-title":"Blood"},{"key":"469_CR14","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphoma. J Clin Oncol 17:1244\u20131253","journal-title":"J Clin Oncol"},{"key":"469_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"469_CR16","first-page":"76","volume":"92","author":"C Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Blood 92:76\u201382","journal-title":"Blood"},{"key":"469_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0959-8049(01)00344-6","volume":"38","author":"K Kim","year":"2002","unstructured":"Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K (2002) Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the revised European\u2013American lymphoma (REAL) classification. Eur J Cancer 38:75\u201381","journal-title":"Eur J Cancer"},{"key":"469_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00280-005-0136-y","volume":"58","author":"JG Kim","year":"2006","unstructured":"Kim JG, Sohn SK, Chae YS, Kim DH, Baek JH, Lee KB, Lee JJ, Chung IJ, Kim HJ, Yang DH, Lee WS, Joo YD, Sohn CH (2006) CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 58:35\u201339","journal-title":"Cancer Chemother Pharmacol"},{"key":"469_CR19","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554\u20133561","journal-title":"Blood"},{"key":"469_CR20","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/sj.leu.2403258","volume":"18","author":"J Lundin","year":"2004","unstructured":"Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR, Kimby E, Osterborg A, Mellstedt H (2004) Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukemia. Leukemia 18:484\u2013490","journal-title":"Leukemia"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0469-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-007-0469-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0469-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0469-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T05:13:31Z","timestamp":1652850811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-007-0469-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,4]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1007\/s00280-007-0469-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,4]]},"assertion":[{"value":"19 November 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}